| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA914: Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | 5 mg/mL concentrate for solution for infusion |
| Reference number | 4945 |
| Indication | Monotherapy for the treatment of the following MSI H or dMMR tumours in adults with: unresectable or metastatic colorectal cancer after previous fluoropyrimidine based combination therapy; advanced or recurrent endometrial carcinoma, who have disease progression on or following prior treatment with a platinum containing therapy in any setting and who are not candidates for curative surgery or radiation; unresectable or metastatic gastric, small intestine, or biliary cancer, who have disease progression on or following at least one prior therapy |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Assessment type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 30/09/2022 |
| NICE guidance | |